Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythromycin estolate and jaundice.

W H Inman, N S Rawson

    British Medical Journal (Clinical Research Ed.)
    |June 18, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Erythromycin estolate did not cause more jaundice than erythromycin stearate or tetracycline. This study found no cases linked to erythromycin estolate, challenging previous suspicions about this antibiotic and jaundice risk.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan.

    Pharmacoepidemiology and drug safety·2004
    Same author

    Ethical issues in pharmacoepidemiologic research using Saskatchewan administrative health care utilization data.

    Pharmacoepidemiology and drug safety·2002
    Same author

    "Effectiveness" in the evaluation of new drugs: a misunderstood concept?

    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2001
    Same author

    Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.

    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2000
    Same author

    Concordance on the recording of cancer in the Saskatchewan Cancer Agency Registry, hospital charts and death registrations.

    Canadian journal of public health = Revue canadienne de sante publique·2000
    Same author

    New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.

    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2000
    Same journal

    Early retirement for consultants.

    British medical journal (Clinical research ed.)·2010
    Same journal

    From COMAR: Essential troika of teaching, research, and clinical care.

    British medical journal (Clinical research ed.)·2010
    Same journal

    Parliament's two way pull on the NHS.

    British medical journal (Clinical research ed.)·2010
    Same journal

    Conference Report: After the summit.

    British medical journal (Clinical research ed.)·2010
    Same journal

    Council election: South Western regional vacancy 1988-90.

    British medical journal (Clinical research ed.)·2010
    Same journal

    Health managers support taxation based service.

    British medical journal (Clinical research ed.)·2010
    See all related articles

    Area of Science:

    • Pharmacovigilance
    • Hepatology
    • Clinical Pharmacology

    Background:

    • Erythromycin estolate was previously suspected of causing more jaundice than other erythromycin formulations or tetracycline.
    • Prescription-event monitoring (PEM) is a valuable tool for assessing drug safety in real-world clinical practice.

    Purpose of the Study:

    • To investigate the potential association between erythromycin estolate and jaundice compared to erythromycin stearate and tetracycline.
    • To evaluate the safety profile of erythromycin estolate regarding hepatotoxicity.

    Main Methods:

    • A prescription-event monitoring study was conducted using data from the Prescription Pricing Authority.
    • Questionnaires were sent to general practitioners regarding jaundice occurrence in patients prescribed erythromycin estolate, erythromycin stearate, or tetracycline.

    Related Experiment Videos

    Main Results:

    • Out of 208 patients, 16 reports of jaundice were identified. Three cases were possibly related to antibiotics, all involving erythromycin stearate.
    • No cases of jaundice were attributed to erythromycin estolate, contradicting prior concerns.
    • The incidence of antibiotic-associated jaundice was estimated to be very low, likely less than 1 in 100.

    Conclusions:

    • Erythromycin estolate does not appear to be a more frequent cause of jaundice than erythromycin stearate or tetracycline.
    • The study provides evidence against the suspected hepatotoxicity of erythromycin estolate.
    • Further pharmacovigilance is warranted to fully understand the rare risks of antibiotic-associated jaundice.